title: Preapoptotic protease calpain-2 is frequently suppressed in adult T-cell leukemia.
abstract: Adult T-cell leukemia (ATL) is one of the most aggressive hematologic malignancies caused by human T-lymphotropic virus type 1 (HTLV-1) infection. The prognosis of ATL is extremely poor; however, effective strategies for diagnosis and treatment have not been established. To identify novel therapeutic targets and diagnostic markers for ATL, we employed focused proteomic profiling of the CD4(+)CD25(+)CCR4(+) T-cell subpopulation in which HTLV-1-infected cells were enriched. Comprehensive quantification of 14 064 peptides and subsequent 2-step statistical analysis using 29 cases (6 uninfected controls, 5 asymptomatic carriers, 9 HTLV-1-associated myelopathy/tropical spastic paraparesis patients, 9 ATL patients) identified 91 peptide determinants that statistically classified 4 clinical groups with an accuracy rate of 92.2% by cross-validation test. Among the identified 17 classifier proteins, α-II spectrin was drastically accumulated in infected T cells derived from ATL patients, whereas its digestive protease calpain-2 (CAN2) was significantly downregulated. Further cell cycle analysis and cell growth assay revealed that rescue of CAN2 activity by overexpressing constitutively active CAN2 (Δ(19)CAN2) could induce remarkable cell death on ATL cells accompanied by reduction of α-II spectrin. These results support that proteomic profiling of HTLV-1-infected T cells could provide potential diagnostic biomarkers and an attractive resource of therapeutic targets for ATL.
authors.affiliation: Laboratory for Biomarker Development, Center of Genomic Medicine, RIKEN, Tokyo, Japan.
authors.forename: Makoto
authors.initials: M
authors.lastname: Ishihara
authors.forename: Natsumi
authors.initials: N
authors.lastname: Araya
authors.forename: Tomoo
authors.initials: T
authors.lastname: Sato
authors.forename: Ayako
authors.initials: A
authors.lastname: Tatsuguchi
authors.forename: Naomi
authors.initials: N
authors.lastname: Saichi
authors.forename: Atae
authors.initials: A
authors.lastname: Utsunomiya
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Nakamura
authors.forename: Hidewaki
authors.initials: H
authors.lastname: Nakagawa
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Yamano
authors.forename: Koji
authors.initials: K
authors.lastname: Ueda
mesh_terms: D000328:Adult; D017209:Apoptosis / Q000276:immunology; D015415:Biomarkers / Q000378:metabolism; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology* / Q000821:virology; D002154:Calpain / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D002453:Cell Cycle / Q000276:immunology; D002460:Cell Line; D002470:Cell Survival / Q000276:immunology; D018450:Disease Progression; D015490:HTLV-I Infections / Q000175:diagnosis / Q000276:immunology / Q000378:metabolism; D015368:Human T-lymphotropic virus 1 / Q000276:immunology*; D006801:Humans; D016130:Immunophenotyping; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000175:diagnosis / Q000378:metabolism / Q000821:virology; D040901:Proteomics; D034741:RNA, Small Interfering / Q000235:genetics; D013049:Spectrin / Q000276:immunology / Q000378:metabolism
chemical_list: D015415:Biomarkers; D034741:RNA, Small Interfering; D013049:Spectrin; D002154:Calpain; C569870:CAPN2 protein, human
references.citation: Anticancer Res. 2003 Mar-Apr;23(2B):1325-31
references.pmid: 12820390
references.citation: Annu Rev Pharmacol Toxicol. 2004;44:349-70
references.pmid: 14744250
references.citation: J Biol Chem. 1992 Mar 5;267(7):4333-7
references.pmid: 1537825
references.citation: PLoS One. 2009 Aug 05;4(8):e6517
references.pmid: 19654865
references.citation: Int J Hematol. 2006 Jul;84(1):63-9
references.pmid: 16867905
references.citation: Neoplasma. 2007;54(1):57-62
references.pmid: 17203893
references.citation: Genome Inform. 2005;16(2):195-204
references.pmid: 16901102
references.citation: Proteomics. 2009 Apr;9(8):2182-92
references.pmid: 19322776
references.citation: Nat Rev Cancer. 2011 May;11(5):364-74
references.pmid: 21508973
references.citation: Retrovirology. 2011 Oct 12;8:81
references.pmid: 21992623
references.citation: Oncogene. 1999 Apr 29;18(17):2667-75
references.pmid: 10348340
references.citation: Blood. 1992 Jan 15;79(2):477-80
references.pmid: 1730092
references.citation: Retrovirology. 2010 Jul 23;7:61
references.pmid: 20653953
references.citation: Proc Natl Acad Sci U S A. 2007 May 8;104(19):8035-40
references.pmid: 17483473
references.citation: Leuk Res. 2011 Mar;35(3):334-9
references.pmid: 20828817
references.citation: PLoS One. 2012;7(4):e34490
references.pmid: 22496815
references.citation: Mol Cell Proteomics. 2002 Nov;1(11):845-67
references.pmid: 12488461
references.citation: J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S124-31
references.pmid: 8797715
references.citation: J Clin Oncol. 2012 Mar 10;30(8):837-42
references.pmid: 22312108
references.citation: Immunology. 2009 Sep;128(1 Suppl):e777-86
references.pmid: 19740339
references.citation: Vascular. 2010 Sep-Oct;18(5):264-8
references.pmid: 20822720
references.citation: Mol Cell Proteomics. 2010 Sep;9(9):1819-28
references.pmid: 20811073
references.citation: Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15163-8
references.pmid: 21876188
references.citation: Biotechniques. 2004 Jan;36(1):139-47
references.pmid: 14740496
references.citation: PLoS One. 2011 Apr 12;6(4):e18567
references.pmid: 21533267
references.citation: Int J Oncol. 2011 Apr;38(4):1047-57
references.pmid: 21305254
references.citation: J Proteome Res. 2007 Sep;6(9):3475-83
references.pmid: 17705522
references.citation: Leukemia. 2005 Jul;19(7):1229-38
references.pmid: 15889159
references.citation: Biochem J. 2006 Mar 15;394(Pt 3):715-25
references.pmid: 16351572